Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases

• Main Authors: Kasandra Bélanger, Umar Iqbal, Jamshid Tanha, Roger MacKenzie, Maria Moreno, Danica Stanimirovic
• Format: Article
• Language: English
• Published: MDPI AG 2019-04-01
• Series: Antibodies
• Subjects: single-domain antibodies; neurodegenerative diseases; brain imaging; blood–brain barrier; delivery
• Online Access: https://www.mdpi.com/2073-4468/8/2/27

Antibodies have become one of the most successful therapeutics for a number of oncology and inflammatory diseases. So far, central nervous system (CNS) indications have missed out on the antibody revolution, while they remain ‘hidden’ behind several hard to breach barriers. Among the various antibody modalities, single-domain antibodies (sdAbs) may hold the ‘key’ to unlocking the access of antibody therapies to CNS diseases. The unique structural features of sdAbs make them the smallest monomeric antibody fragments suitable for molecular targeting. These features are of particular importance when developing antibodies as modular building blocks for engineering CNS-targeting therapeutics and imaging agents. In this review, we first introduce the characteristic properties of sdAbs compared to traditional antibodies. We then present recent advances in the development of sdAbs as potential therapeutics across brain barriers, including their use for the delivery of biologics across the blood–brain and blood–cerebrospinal fluid (CSF) barriers, treatment of neurodegenerative diseases and molecular imaging of brain targets.